Cellex Symposium Explores Cell Therapy Turning Point
Cellex Cell Professionals gathered more than 100 researchers, clinicians and industry experts in Cologne for its 2026 symposium.
Updated on Nov. 17, 2026 in Biotech

Cellex Cell Professionals held the Cellex Symposium 2026 on November 8 at the Wasserturm Hotel Cologne, themed "Cell and Gene Therapy at a Turning Point." The event featured 10 scientific presentations across three sessions.
Why it matters
The symposium brings together researchers, clinicians and industry experts to discuss the next stage of cell and gene therapy development. Its discussions covered regulated artificial intelligence use and whether product quality can be maintained across manufacturing sites.
The symposium drew more than 100 researchers, clinicians and industry experts for 10 presentations across three sessions. Cellex, which has more than 10 years of experience manufacturing autologous and allogeneic products, did not report session outcomes in the announcement.
The players
Cellex Cell Professionals
Cellex grew from an apheresis service provider for stem cell donor registries into a cell therapy contract development and manufacturing organization serving pharmaceutical, biotechnology and academic partners.
The details
The opening session covered moving cell therapies into the clinic, including genome-engineered T cells, allogeneic immune-cell therapy in sepsis and GMP compliance. The second session addressed hard-to-treat cancers and genetic disorders, from peptide vaccines and gene editing platforms to PRAME-directed TCR T cells, while the closing session covered GMP raw materials, integrated CDMO models and China's role in global biotech.
Timeline
November 8, 2026: Cellex Symposium 2026 held in Cologne
November 17, 2026: Press release published about the symposium
Tech Race
The symposium's focus on GMP compliance and integrated CDMO models reflects a shift in cell therapy manufacturing from single-site production toward scalable, multi-site operations. Discussions of AI in regulated environments place the field in an emerging contest over how biotech firms modernize quality control.
Cell and gene therapies discussed at the symposium could affect how future treatments are manufactured and made available to patients. Improvements in GMP compliance and multi-site production may influence the consistency and scale of these therapies over time.
The takeaway
Advances in manufacturing quality, not only scientific discovery, will determine how quickly cell therapies reach patients. Following how companies address GMP compliance and integrated production can help readers track progress in the field.
Further reading
Explore more on Biotech developments shaping cell and gene therapy.
Source note: This article includes information reported by Adnkronos.







